𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor

✍ Scribed by Bernardo Nuche-Berenguer; Sergio Portal-Núñez; Paola Moreno; Nieves González; Alicia Acitores; Ana López-Herradón; Pedro Esbrit; Isabel Valverde; María L. Villanueva-Peñacarrillo


Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
202 KB
Volume
225
Category
Article
ISSN
0021-9541

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Glucagon‐like peptide 1 (GLP‐1) controls glucose metabolism in extrapancreatic tissues through receptors other than the pancreatic cAMP‐linked GLP‐1 receptor; also, GLP‐1 induces an insulin‐ and PTH‐independent bone anabolic action in insulin‐resistant and type‐2 diabetic rats. Here we searched for the presence and characteristics of GLP‐1 receptors in osteoblastic MC3T3‐E1 cells. [^125^I]‐GLP‐1 specific binding to MC3T3‐E1 cells was time‐ and temperature‐dependent, reaching maximal value at 30 min at 25°C; in these conditions, [^125^I]‐GLP‐1 binding was dissociable, and displaced by GLP‐1, partially by GLP‐2, but not by exendin‐4 (Ex‐4), exendin‐9 (Ex‐9), glucagon or insulin; Scatchard analysis of the unlabeled GLP‐1 data showed high and low affinity binding sites; cross‐linking of GLP‐1 binding revealed an estimated 70 kDa band, almost undetectable in the presence of 10^−6^ M GLP‐1. GLP‐1, Ex‐9, insulin or glucagon failed to modify cellular cAMP content, while GLP‐2 and Ex‐4 increased it. However, GLP‐1 induced an immediate hydrolysis of glycosylphosphatidylinositols (GPIs) generating short‐lived inositolphosphoglycans (IPGs), and an increase in phosphatidylinositol‐3 kinase (PI3K) and mitogen activated protein kinase (MAPK) activities; Ex‐4 also affected GPIs, but its action was delayed with respect to that of GLP‐1. This incretin was found to decrease Runx2 but increased osteocalcin gene expression, without affecting that of osteoprotegerin or the canonical Wnt pathway activity in MC3T3‐E1 cells which do not express the pancreatic GLP‐1 receptor. Our data demonstrate for the first time that GLP‐1 can directly and functionally interact with osteoblastic cells, possibly through a GPI/IPG‐coupled receptor. J. Cell. Physiol. 225: 585–592, 2010. © 2010 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Comparison of the anti-diabetic effects
✍ Nigel Irwin; Paula L. McClean; Roslyn S. Cassidy; Finbarr P. M. O'Harte; Brian D 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB

## Abstract ## Background The two major incretin hormones, glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) are being actively explored as anti‐diabetic agents because they lower blood glucose through multiple mechanisms. The rapid inactivation of GIP and GLP‐

Association of the glucocorticoid recept
✍ Fanghong Chen; Cheryl S. Watson; Bahiru Gametchu 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 655 KB

Using the combination of a cDNA library prepared from membrane glucocorticoid (mGR)-enriched S-49 cells and a mouse leukocyte genomic library, we have cloned a 7.3 kb full-length glucocorticoid receptor 1A cDNA. Primer extension, 5ЈRACE, and long distance PCR identified the transcription start site

NPY revealed as a critical modulator of
✍ Liliana Teixeira; Daniela M. Sousa; Ana Filipa Nunes; Mónica M. Sousa; Herbert H 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 258 KB 👁 1 views

## Abstract Neuropeptide Y (NPY) has recently emerged as a potential regulator of bone homeostasis. However, the relevance of NPY's role in osteoblast activity and the biological functions involving NPY receptors in bone homeostasis remain to be clarified. Here we report that chronically elevated N